ARWR vs CRVS

Arrowhead Pharmaceuticals maintains strong 10x growth potential within 3-5 years, leveraging its advanced TRiM RNAi platform and a robust pipeline targeting high-value indications. The positive Phase 3 data for ARO-AAT (fazirsiran) in Alpha-1 Antitrypsin Deficiency, recently announced (Q4 2025/early Q1 2026), remains a pivotal catalyst, positioning the company for imminent regulatory submission an...

Corvus Pharmaceuticals demonstrates significantly enhanced 10x potential, largely driven by compelling Phase 2 data for CPI-818 in T-cell lymphoma, a critical de-risking event. This clinical validation strengthens its market opportunity in high-unmet-need oncology niches and expands its competitive moat through proprietary IP and clinical efficacy. The leadership team, particularly Dr. Richard Mil...